|
WO2019231803A1
|
|
Combination therapy for soft tissue sarcoma
|
|
WO2019070497A1
|
|
Combination therapy for cancer
|
|
EP3595717A1
|
|
Combination therapy for pancreatic cancer
|
|
WO2018144334A1
|
|
Dosing regimen for anti-csf-1r antibody
|
|
WO2018081512A1
|
|
Combination of an anti-vegfr-2 antibody and an anti-pd-l1 antibody for the treatment of cancer
|
|
CN110036030A
|
|
The combination treatment of cancer
|
|
WO2017210119A1
|
|
Combination of ramucirumab and pembrolizumab for the treatment of certain cancers
|
|
US2017333554A1
|
|
Dosing regimen
|
|
TW201716085A
|
|
Combination therapy for cancer
|
|
TW201711702A
|
|
Therapies utilizing compounds to fibroblast growth factor receptor-3 (FGFR3)
|
|
MX2016016866A
|
|
Therapy for gist.
|
|
BR112016030291A2
|
|
combination therapy
|
|
TW201526914A
|
|
Compounds to fibroblast growth factor receptor-3 (fgfr3) and methods of treatment
|
|
TN2013000068A1
|
|
Anti-vegfr-3 antibody compositions
|
|
AR086044A1
|
|
ANTIBODIES THAT SPECIFICALLY JOIN A C-KIT EXTRACELLULAR DOMAIN AND USES OF THE SAME
|
|
TW201223543A
|
|
Anti-vegfr-3 antibody compositions
|
|
JO3291B1
|
|
Antibodies against csf-1r
|
|
WO2010080463A1
|
|
Antibody humanization
|
|
WO2010056893A1
|
|
Humanization and affinity-optimization of antibodies
|
|
UA101988C2
|
|
ANTIBODIES AGAINST HUMAN TRANSFORMING GROWTH FACTOR BETA RECEPTOR II (TGFβRII)
|
